<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>The latest announcement is out from Duality Biotherapeutics, Inc. ( (HK:9606) ). Duality Biotherapeutics has exercised its exclusive cost and profit/loss sharing option with BioNTech for DB-1311/BNT324 in the U.S. market, following progress under their existing license and collaboration agreement. The move requires Duality to reimburse BioNTech for past U.S.-attributed development costs but grants it a direct share of future development expenses and commercialization economics for the first DB-1311/BNT324 product in the United States. The board cited encouraging clinical data and substantial commercial potential for DB-1311/BNT324, a next-generation B7-H3-targeting topoisomerase-I inhibitor ADC currently in multiple Phase 1/2 and Phase 2 trials across advanced solid tumors and lung cancers. By opting into the U.S. cost and profit-sharing structure, Duality is deepening its strategic exposure to a key oncology asset in a major market, potentially enhancing long-term value for shareholders while assuming greater financial and development risk amid ongoing clinical uncertainty. The most recent analyst rating on (HK:9606) stock is a Buy with a HK$383.47 price target. To see the full list of analyst forecasts on Duality Biotherapeutics, Inc. stock, see the HK:9606 Stock Forecast page. More about Duality Biotherapeutics, Inc. Duality Biotherapeutics, Inc. is a Cayman Islands–incorporated biopharmaceutical company focused on developing next-generation antibody-drug conjugates and immuno-oncology therapies. The company targets solid tumors with innovative candidates such as DB-1311/BNT324, aiming to address high unmet medical needs in major oncology markets including the United States. Average Trading Volume: 863,794 Technical Sentiment Signal: Strong Sell Current Market Cap: HK$23.15B </div>

BNTX

ARKG

Duality Biotherapeutics has exercised its cost and profit-sharing option with BioNTech for DB-1311/BNT324 in the U.S. This move allows Duality to share future development costs and commercialization profits while reimbursing BioNTech for past expenses. The decision is based on positive clinical data and the potential of DB-1311/BNT324, which is in various trials for advanced solid tumors and lung cancers. Analysts rate Duality Biotherapeutics stock as a Buy with a price target of HK$383.47, indicating strong market interest despite the associated risks.

Tip Ranks

BioNTech SE

iShares Biotechnology ETF

Ark Genomic Revolution ETF

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

DUALITYBIO-B

Duality Biotherapeutics Exercises U.S. Cost and Profit-Sharing Option for BioNTech ADC